Hormonal maintenance therapy may improve survival in women with chemo-resistant rare ovarian or peritoneum cancer

MD安德森新闻发布2017年2月21日

对于女性卵巢上皮癌或腹膜癌，被称为低档浆液性癌（LGSC），激素维持治疗（HMT）可显著提高生存的一种罕见的亚型，根据研究人员在一项新的研究乐动体育LDsports中国得克萨斯大学MD安德森癌症中心的大学。

这项研究乐动体育LDsports中国发表在临床肿瘤学杂志和已被更新，因为它是第一个提出在临床肿瘤学美国社会的2016年年度会议。

According to the researchers, LGSC accounts for just 10 percent of serous carcinomas of the ovary/peritoneum. It is typically diagnosed in women, as early as in their 40s and 50s (however, teenagers and women in their 20s and 30s also may be diagnosed). Patients usually present with advanced disease.

MD安德森已经发现罕见卵巢癌的这一领域的悠久历史 - 出版于2004年的一项研究，改变了浆液性癌进行分级的方式，从而识别LGSC。MD安德森研究还表明，采乐动体育LDsports中国用高档浆液性癌相比LGSC相对化疗耐药，说David M. Gershenson, M.D., professor, Gynecologic Oncology and Reproductive Medicine.

如果这种新的追溯数据的随机研究来验证，结果有一天可以代表显著改善护理的一线标准。

“有对这些患者真正的未满足的需要 - 妇女，这种疾病的大约有70％会在某个时候出现癌症复发，” Gershenson，该研究的通讯作者说。“我们集团发表的研究表明激素治疗显示，在反乐动体育LDsports中国复设置的承诺，大多数患者响应或病情稳定。它是随着时间的推移自然发展，我们开始研究这件事前，妇女接受他们的主要化疗后“。

在此回顾性队列研究中，研究人员分析了II-IV期LGSC在MD安德森19乐动体育LDsports中国81年至2013年间处理，评估HMT的效果，从203名妇女的数据，以监测相比，手术和化疗后。谁收到HMT（70例），女性表现为64.9个月，平均无进展生存期（PFS）26.4个月的观察组（133例）相比。总生存期（OS）是继HMT115.7个月，与102.7个月为观察组。

Further, among 149 women who showed no evidence of disease following completion of primary chemotherapy, HMT appears to have resulted in even greater survival: 81.1 vs. 30 months PFS; and 191.3 vs.106.8 months OS.

“Hormonal therapy has shown promising results in reducing cancer recurrence, and there is increasing interest in integrating this approach into first-line therapy,” said Gershenson. “If confirmatory research in a clinical trial setting shows hormonal maintenance therapy can prevent or delay recurrence of this cancer subtype, it would be practice changing.”

Though recruitment for this patient population is challenging given the rarity of the disease, Gershenson noted that a prospective international Phase III clinical trial has been designed. The study will compare: chemotherapy and observation; chemotherapy and HMT; and hormonal therapy alone, which also has shown early promise in other studies.

In addition to Gershenson, authors on the all-MD Anderson study include: Diane Bodurka, M.D., Robert L. Coleman, M.D., Karen H. Lu, M.D., chair; and Charlotte Sun, all of the Department of Gynecologic Oncology and Reproductive Medicine; and Anais Malpica, M.D., of Pathology.

The study was supported by the Sara Brown Musselman Fund for Serous Ovarian Cancer Research and the MD Anderson Cancer Center Support Grant from the National Cancer Institute (No. P30 CA016672).